Spectrum Pharmaceuticals, Inc. (Nasdaq GS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced that its Board of Directors has terminated Rajesh C. Shrotriya, MD without cause from his position as Chief Executive Officer. “The Board of Directors thanks, Dr. Shrotriya for his contributions to Spectrum over the past fifteen years,” said Dr. Krassner, Chairman. Rajesh Shrotiya was the last standing CEO of Indian Origin in Las Vegas to hold a position in a public traded company.  InRead More